TNF and infection: Meta-analysis is an interesting method to detect such a risk of a relatively rare event: a recent meta-analysis of randomised placebo-controlled trials of monoclonal anti-TNF-α antibodies (infliximab, adalimumab) found a pooled odds ratio (OR) for serious infections of 2.0 (95% confidence interval (CI), 1.3 to 3.1) in TNF-α blocker treated patients.17 However, individually, the trials had failed to demonstrate this increased risk of serious infections.